에 대한 최신 뉴스 CISO Global (NASDAQ:CISO) 주식

CISO Global

CISO Global Inc provides cybersecurity services. The services are used to protect client's data, financial information, intellectual property, and business reputation. The services include penetration testing, security remediation, compliance auditing, vulnerability assessment, and others. Geographically, the company operates in U.S., Chile and All other countries. The maximum revenue is generated from U.S.

CISO Global Inc

Vital Farms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VITL#NASDAQ">VITL</a>) FY2025 Revenue expected to be more than $740.00M vs $741.67M Est

News

Guidance

VITL

Vital Farms FY2025  Revenue expected to be more than $740.00M vs $741.67M Est

Telsey Advisory Group analyst Dana Telsey maintains Steven Madden (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHOO#NASDAQ">SHOO</a>) with a Market Perform and maintains $24 price target.

Price Target

Analyst Ratings

SHOO

Telsey Advisory Group Maintains Market Perform on Steven Madden, Maintains $24 Price Target

Earnings

Earnings Misses

RPRX

Royalty Pharma Q1 Adj. EPS $1.06 Misses $1.59 Estimate,

Vital Farms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VITL#NASDAQ">VITL</a>) reported quarterly earnings of $0.37 per share which beat the analyst consensus estimate of $0.28 by 32.14 percent. This is a 13.95 percent decrease over earnings of $0.43 per share from the same period last year. The company reported quarterly sales of $162.19 million which missed the analyst consensus estimate of $162.96 million by 0.47 percent. This is a 9.64 percent increase over sales of $147.93 million the same period last year.

Earnings Beats

Vital Farms Q1 EPS $0.37 Beats $0.28 Estimate, Sales $162.19M Miss $162.96M Estimate

Telsey Advisory Group analyst Dana Telsey maintains Honest Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HNST#NASDAQ">HNST</a>) with a Market Perform and maintains $7 price target.

HNST

Telsey Advisory Group Maintains Market Perform on Honest Co, Maintains $7 Price Target

Nuveen Churchill Direct (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NCDL#NYSE">NCDL</a>) reported quarterly earnings of $0.53 per share which missed the analyst consensus estimate of $0.56 by 5.36 percent. This is a 5.36 percent decrease over earnings of $0.56 per share from the same period last year. The company reported quarterly sales of $53.59 million which missed the analyst consensus estimate of $56.01 million by 4.32 percent. This is a 3.86 percent increase over sales of $51.59 million the same period last year.

NCDL

Nuveen Churchill Direct Q1 EPS $0.53 Misses $0.56 Estimate, Sales $53.59M Miss $56.01M Estimate

Telsey Advisory Group analyst Joseph Feldman maintains Costco Wholesale (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COST#NASDAQ">COST</a>) with a Outperform and maintains $1100 price target.

COST

Telsey Advisory Group Maintains Outperform on Costco Wholesale, Maintains $1100 Price Target

WIIM

Canadian Natural Resources shares are trading higher after the company reported better-than-expected Q1 financial results.

ellgistics Health, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WGRX#NASDAQ">WGRX</a>), a technology-first pharmaceutical distribution and healthcare infrastructure company, today announced a new initiative to pioneer the use of XRP, a blockchain-based digital asset, as both a treasury reserve and a real-time payments infrastructure-which management believes, upon successful commercialization, would make Wellgistics among the first publicly traded healthcare companies to deploy XRP in this manner.
This XRP payment initiative is supported by Wellgistics Health's $50 million Equity Line of Credit (ELOC), the proceeds of which may be utilized to further develop and unlock programmable liquidity and on-demand financial infrastructure designed to eliminate banking delays, reduce cost, and increase transparency across its national healthcare network.
"At Wellgistics Health, we challenge the idea that healthcare has to be tethered to legacy systems, bloated intermediaries, and slow-moving money," said Brian Norton, CEO of Wellgistics Health. "We are developing a platform that connects manufacturers directly to pharmacies and patients-bypassing the red tape and placing control back in the hands of those who deliver care. Our blockchain-enabled payment system and ledger is just the next logical step in healthcare evolution, allowing us to hardwire speed, liquidity, and transparency into a system that's long been starved of all three. I believe that the future winners in healthcare won't be the companies with the biggest buildings…they'll be those with the fastest rails, cleanest data, and most efficient platforms. We're betting on infrastructure…not inertia."
Why XRP? Why Now?
We believe that there are certain advantages to integrating XRP and its related infrastructure into its healthcare ecosystem. These include, among others:
Speed: XRP settles transactions in 3-5 seconds vs. 1-3 days for ACH or wire transfers, allowing for near real-time settlement among pharmacies, suppliers, and manufacturers.
Cost: Less than $0.0002 per transfer vs. $10-$30 for standard bank wires.
Transparency: All transactions are logged on the XRP Ledger for real-time compliance, rebate tracking, and auditability.
Scope: Supports global vendor payouts with significantly low foreign exchange and wire transfer fees.
Flexibility: Allows for XRP-backed lines of credit to support independent pharmacy liquidity.
These benefits will support faster vendor payments, performance-based rebates, and embedded liquidity tools for pharmacies and manufacturers in the Wellgistics ecosystem.
Use Cases Across the Ecosystem
Real-time settlement between pharmacies, suppliers, and manufacturers
Smart rebates calculated automatically based on real-world data
XRP-backed credit lines to enhance liquidity for independent pharmacies
Global vendor payouts with near-zero foreign transaction and wire costs
Immutable compliance layer supporting DSCSA reporting and pricing validation
"We're working to unlock capital velocity with surgical precision," said Mark DiSiena, CFO of Wellgistics Health. "We believe that our XRP-powered infrastructure will allow us to run leaner, faster, and with more control than any of our peers in pharma infrastructure."
The Market Is Moving-And Wellgistics Intends to Lead
XRP is gaining momentum across global institutions, as demonstrated by the following:
CME Group to launch XRP futures for institutional access → CME will launch cash-settled XRP futures contracts in May 2025 to meet rising institutional demand.¹
Mastercard identifies XRP as a bridge currency for cross-border payments → Mastercard's 2025 report highlights XRP as a top solution for global remittances and cost efficiency.²
Ripple acquires prime brokerage firm Hidden Road for $1.25B → This landmark acquisition expands XRP's footprint in institutional liquidity and asset servicing.³
Ripple receives regulatory licensing in Dubai → Ripple became the first blockchain payment provider licensed by the DFSA to operate crypto-based financial services in the UAE.⁴
Ripple expands real-world cross-border payment corridors in Brazil and Portugal → Ripple now enables live XRP-powered remittances between LATAM and Europe through its partnership with Unicâmbio.⁵
"Others are waiting for change. We're building it," Norton added. "I strongly believe that our XRP initiative positions Wellgistics Health years ahead of the curve-and squarely at the center of where healthcare and fintech converge."

WGRX

Wellgistics Health Announces $50M Credit Facility And Launches XRP-Powered Payment Initiative

Shopify (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHOP#NASDAQ">SHOP</a>) sees Q2 sales of $2.536 billion-$2.577 billion vs $2.50 billion analyst estimate.

SHOP

Shopify Sees Q2 Sales $2.536B-$2.577B vs $2.50B Est

Stagwell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STGW#NASDAQ">STGW</a>) affirms FY2025 Adj EPS guidance from $0.75-$0.88 to $0.75-$0.88 vs $0.84 analyst estimate. Affirms FY2025 sales outlook from $3.07 billion to $3.07 billion vs $2.89 billion estimate.

STGW

Stagwell Affirms FY2025 Adj EPS Guidance of $0.75-$0.88 vs $0.84 Est; Affirms FY2025 Sales Guidance of $3.07B vs $2.89B Est

FTNT

Fortinet shares are trading lower. The company reported Q1 financial results.

Chardan Capital analyst Rudy Li initiates coverage on Centessa Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNTA#NASDAQ">CNTA</a>) with a Buy rating and announces Price Target of $30.

Initiation

CNTA

Chardan Capital Initiates Coverage On Centessa Pharmaceuticals with Buy Rating, Announces Price Target of $30

Whitestone REIT Expands Austin Footprint With Acquisition Near Apple, Tesla Campuses

Stagwell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STGW#NASDAQ">STGW</a>) reported quarterly earnings of $0.12 per share which missed the analyst consensus estimate of $0.15 by 20 percent. This is a 25 percent decrease over earnings of $0.16 per share from the same period last year. The company reported quarterly sales of $651.74 million which missed the analyst consensus estimate of $664.40 million by 1.91 percent. This is a 2.73 percent decrease over sales of $670.06 million the same period last year.

Stagwell Q1 Adj. EPS $0.12 Misses $0.15 Estimate, Sales $651.74M Miss $664.40M Estimate

SEZL: 39% &#x7C; <a href="https://www.benzinga.com//node/45280082">Sezzle Shares Are Trading Higher After The Company Reported Better Then Expected Q1 EPS And Sales</a>
&nbsp;
LZ: 18% &#x7C; <a href="https://www.benzinga.com//node/45280032">LegalZoom.com shares are trading higher after the company reported better-than-expected Q1 sales results and issued Q2 sales guidance with its midpoint above estimates. Also, the company issued FY25 sales guidance above estimates.</a>
&nbsp;
PRFX: 63% &#x7C; <a href="https://www.benzinga.com//node/45267896">PainReform shares are trading higher after the company announced it launched a strategic AI pilot with Econergy Renewable Energy.</a>

Movers

Trading Ideas

PRFX

SEZL

Market-Moving News for May 8th

Royalty Pharma Q1 Sales $568.00M Miss $705.34M Estimate

Shopify shares are trading lower. The company reported Q1 financial results.

Kenvue updated its outlook for Full Year 2025 to reflect current foreign exchange rates, as well as the estimated impact from higher costs due to tariffs in place as of May 7, 2025. The Company expects:
<ul>
<li>Net sales increase of +1% to +3% year-over-year, with Organic sales growth of +2% to +4% (unchanged) and a ~1% headwind from foreign currency translation.</li>
<li>Adjusted operating income margin decline year-over-year, reflecting the estimated impact of tariffs.</li>
<li>Adjusted diluted earnings per share about flat year-over-year, including a low-single-digit unfavorable impact from foreign currency.</li>
</ul>
 &nbsp;

KVUE

Kenvue Raises FY2025 Net Sales Guidance from $15.30B-$15.61B to $15.61B-$15.92B vs $15.43B Est

Entrada Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRDA#NASDAQ">TRDA</a>) reported quarterly losses of $(0.42) per share which beat the analyst consensus estimate of $(0.76) by 44.74 percent. This is a 161.76 percent decrease over earnings of $0.68 per share from the same period last year. The company reported quarterly sales of $20.56 million which beat the analyst consensus estimate of $10.17 million by 102.12 percent. This is a 65.23 percent decrease over sales of $59.12 million the same period last year.

TRDA

Entrada Therapeutics Q1 EPS $(0.42) Beats $(0.76) Estimate, Sales $20.56M Beat $10.17M Estimate

Press Releases

CISO Global Announces Strategic Investment to Accelerate Growth and Profitability

CISO Global's Compliance Division Passes CMMC Audit, Paving the Way to C3PAO Certification

CISO Global Continues to Advance AI-Powered Security Solutions within Microsoft and Amazon Cloud

CISO Global Launches AI-Powered Cloud Security Offering to Strengthen Enterprise Cyber Resilience

CISO Global's AI-Powered Penetration Testing and Analysis Tool to make Real-time Assessments a Reality

CISO Global Comments on Stock Volatility: No Insider Sales — Market Makers Likely Behind Stock Pressure

CISO Global Announces Pay Off of Highest-Interest Debt, Extends $7M in Convertible Notes

CISO Global achieves profitability

CISO Global Eliminates Convertible Debt as Profitability Fuels Investor Confidence

CISO Global brings AI to $50 Billion Insurance Market with Cyber Assurance Group Strategic Partnership to Deliver Innovative Cyber Technology and Insurance Solutions

Comments

CISO Global

뉴스

에 대한 최신 뉴스 CISO Global (NASDAQ:CISO) 주식

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌